REGN 10-Q Quarterly Reports

Regeneron Pharmaceuticals, Inc. reported strong financial results for the nine months ended September 30, 2025, with total revenues of $10.46 billion, a slight increase from the same period in 2024. Net income also saw a positive trend, reaching $3.66 billion, up from $3.49 billion in the prior year. Diluted earnings per share were $33.61, an increase from $30.23. The company's product sales, while experiencing a decline in EYLEA revenue due to increased competition and the transition to EYLEA HD, were bolstered by significant growth in Dupixent and Libtayo sales. Collaboration revenue, primarily from Sanofi, also showed robust growth, driven by strong Dupixent performance. Operating expenses increased due to higher R&D investments, particularly in direct R&D for key programs, though SG&A expenses decreased. The company continued its share repurchase program and declared regular quarterly dividends, underscoring a commitment to returning capital to shareholders.

Regeneron Pharmaceuticals, Inc. (REGN) reported its financial results for the quarter and six months ended June 30, 2025. Total revenues for the six months ended June 30, 2025, were $6.704 billion, a slight increase from $6.692 billion in the same period of 2024. Net income for the first six months of 2025 was $2.200 billion, or $20.02 per diluted share, compared to $2.154 billion, or $18.68 per diluted share, in the prior year's period. The company's balance sheet shows total assets of $38.219 billion as of June 30, 2025, and total stockholders' equity of $29.939 billion. The company saw a decrease in net product sales, primarily driven by a significant decline in EYLEA sales, which was partially offset by growth in EYLEA HD and Dupixent. Collaboration revenues, largely from the Sanofi and Bayer partnerships, showed a substantial increase, driven by higher profit shares, particularly from Dupixent. Operating expenses, notably research and development, increased year-over-year, reflecting continued investment in the company's pipeline. Investors should note the ongoing legal proceedings related to EYLEA biosimilar challenges and the company's active share repurchase program, which repurchased approximately $2.122 billion of common stock during the first six months of 2025. The company also declared and paid quarterly dividends.

Regeneron Pharmaceuticals, Inc. reported mixed results for the first quarter of 2025. Total revenues decreased slightly year-over-year to $3.03 billion from $3.15 billion, primarily driven by a significant decline in U.S. EYLEA sales due to competitive pressures and the transition to EYLEA HD. However, this was partially offset by strong growth in Dupixent and a solid performance from EYLEA HD in the U.S. Net income increased to $808.7 million, or $7.27 per diluted share, compared to $722.0 million, or $6.27 per diluted share, in the prior year's quarter. This improvement was supported by an increase in collaboration revenue, particularly from Sanofi, and a favorable shift in other income (expense), net. The company also announced its first quarterly cash dividend and continued its share repurchase program, signaling a commitment to returning capital to shareholders.

Regeneron Pharmaceuticals, Inc. reported solid financial results for the nine months ended September 30, 2024, with total revenues reaching $10.41 billion, an increase of 7.5% compared to the same period in the prior year. Net income also saw a significant rise, up 25% to $3.49 billion. This growth was driven by strong performance across key products, notably Dupixent and EYLEA HD, which showed substantial revenue increases of 25% and approximately 4% respectively in their respective segments. The company also saw positive growth in Libtayo and Praluent. Research and development expenses increased by approximately 14% year-over-year, reflecting continued investment in the company's pipeline. The company ended the period with a strong liquidity position, with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities, while also actively repurchasing shares under its authorized program.

Regeneron Pharmaceuticals, Inc. reported strong financial results for the second quarter and first half of 2024, demonstrating robust revenue growth and increased profitability. Total revenues increased by 12% year-over-year for the second quarter to $3.55 billion and by 6% for the first half to $6.69 billion, driven by significant contributions from its key products, particularly Dupixent and EYLEA HD. Net product sales saw a healthy increase, with Dupixent sales up 27% in the second quarter and 26% in the first half. EYLEA HD and EYLEA combined U.S. net sales showed a slight increase of 2%, with EYLEA HD sales contributing $304.2 million in the quarter, reflecting strong patient adoption. Collaboration revenue also saw a substantial increase, primarily due to higher profit shares from Dupixent sales. The company's net income grew significantly, reaching $1.43 billion in the second quarter, a 48% increase year-over-year, resulting in diluted EPS of $12.41. For the first half, net income increased by 21% to $2.15 billion, with diluted EPS of $18.68. The company also continued its share repurchase program, repurchasing $601.4 million in the second quarter, underscoring a commitment to returning capital to shareholders.

Regeneron Pharmaceuticals, Inc. reported a slight decrease in total revenues to $3,145.0 million for the first quarter of 2024, down from $3,162.1 million in the same period last year. This was primarily driven by a decrease in EYLEA net product sales in the U.S., offset by strong growth in Dupixent, Libtayo, and Praluent. Net income saw a decline to $722.0 million from $817.8 million, resulting in diluted EPS of $6.27 compared to $7.17 year-over-year. Despite the revenue dip, the company demonstrated solid operational cash flow generation. Investment in research and development increased significantly, reflecting continued commitment to pipeline expansion. The company also continues its share repurchase program, with $1.233 billion remaining authorization as of March 31, 2024, and authorized an additional $3.0 billion in April 2024.

Regeneron Pharmaceuticals, Inc. reported a strong third quarter of 2023, driven by robust growth in key products like Dupixent and Libtayo, alongside collaboration revenues. Total revenues increased to $3.36 billion, a 14.5% rise year-over-year, with net income reaching $1.01 billion. The company also saw significant growth in its marketable securities portfolio and continued to execute its share repurchase program, returning capital to shareholders. Despite a slight decline in Eylea U.S. net product sales due to increased competition, the approval of Eylea HD in August 2023 provides a significant opportunity for future growth in the ophthalmology market. The company's R&D expenses increased, reflecting ongoing investment in its diverse pipeline, including advancements in oncology and immunology. Regeneron maintains a solid financial position with substantial cash and marketable securities, providing flexibility for future investments and strategic initiatives.

Regeneron Pharmaceuticals, Inc. (REGN) reported solid financial results for the second quarter and first half of 2023, demonstrating continued revenue growth driven primarily by Dupixent and Libtayo, which offset a decline in EYLEA sales in the US. Total revenues increased by 10.5% year-over-year for the first six months of 2023. Net income also saw an increase, reaching $1.79 billion for the first half of the year. The company's strong financial position is supported by a robust cash balance and significant investments in research and development, underscoring its commitment to pipeline expansion and innovation. The company is strategically navigating the competitive landscape for EYLEA, facing increased competition and awaiting regulatory decisions on its next-generation aflibercept 8 mg. However, the significant growth in Dupixent and Libtayo, along with progress in its robust pipeline of over 30 product candidates, positions Regeneron for sustained long-term growth. Investors should monitor upcoming regulatory decisions, especially for aflibercept 8 mg, and the continued commercial performance of key growth drivers like Dupixent.

Regeneron Pharmaceuticals, Inc. reported its first-quarter 2023 financial results, demonstrating revenue growth and a strong balance sheet. Total revenues increased to $3.16 billion, up from $2.97 billion in the same period last year, driven primarily by a significant increase in collaboration revenue, particularly from the Sanofi antibody collaboration. Net product sales saw a modest increase of $29 million to $1.67 billion, with notable growth in Libtayo and Evkeeza offsetting a decline in EYLEA U.S. sales. The company maintained a solid financial position with approximately $3.9 billion in cash and cash equivalents and over $11 billion in marketable securities. Research and development expenses increased significantly, reflecting continued investment in its robust pipeline, including advancements in immunology, inflammation, and oncology programs. The company also continued its share repurchase program, demonstrating a commitment to returning capital to shareholders.

Regeneron Pharmaceuticals, Inc. reported third-quarter and year-to-date results for the period ending September 30, 2022, showing a decrease in total revenues compared to the prior year, largely driven by a significant drop in REGEN-COV sales. Despite this, the company demonstrated robust growth in key products like Dupixent and EYLEA, with Dupixent sales up 40% year-over-year. Operationally, R&D expenses increased, reflecting ongoing investments in the pipeline, and SG&A expenses also rose, partly due to increased commercialization efforts for Libtayo after its global rights acquisition. The company's balance sheet remains strong, with substantial cash and marketable securities. Significant investments were made in acquiring the worldwide rights for Libtayo, impacting cash flows. The company continues its share repurchase program, with approximately $1.186 billion remaining authorized. Investors should note the ongoing litigation concerning Praluent and EYLEA patents, as well as various government investigations. The company's future performance is heavily reliant on the continued success of EYLEA and Dupixent, alongside the progression of its pipeline products.

Regeneron Pharmaceuticals, Inc. reported its financial results for the second quarter and first half of 2022. The company saw a significant decrease in total revenues for both the three and six-month periods compared to the prior year, primarily driven by the absence of REGEN-COV sales, which were substantial in the first half of 2021. Despite the revenue decline, Regeneron demonstrated strong operational cash flow generation. Key product sales, particularly for EYLEA and Dupixent, showed robust year-over-year growth, indicating continued strong demand for these core products. The company also made significant strategic moves, including the acquisition of Checkmate Pharmaceuticals, which added an oncology pipeline asset, and an amendment to its Immuno-oncology collaboration with Sanofi, granting Regeneron exclusive worldwide rights to Libtayo. These strategic actions, coupled with a strong cash position and an ongoing share repurchase program, position Regeneron for future growth despite near-term revenue headwinds from the REGEN-COV wind-down.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong revenue growth in the first quarter of 2022, driven by significant increases in collaboration revenue from key partnerships, particularly with Sanofi and Bayer. While net product sales saw a slight decline year-over-year, largely due to the absence of REGEN-COV sales compared to the prior year's COVID-19 surge, this was more than offset by robust performance in collaboration revenue streams. The company's ongoing investment in research and development remains substantial, reflecting its commitment to pipeline advancement. Financially, Regeneron maintained a healthy cash position and liquidity, supported by strong operating cash flow. The company continued its share repurchase program, returning capital to shareholders. Despite legal proceedings and market uncertainties, Regeneron's diversified portfolio and strategic collaborations position it for continued growth and innovation in the biotechnology sector.

Regeneron Pharmaceuticals, Inc. (REGN) reported a strong third quarter for 2021, demonstrating significant revenue and profit growth driven by robust performance across its key products. Total revenues increased by 55% year-over-year to $3.45 billion, with net product sales growing substantially, notably from EYLEA and Dupixent. The company also saw a significant boost from REGEN-COV, its COVID-19 antibody treatment, which contributed substantially to revenue in the period. Net income rose by an impressive 94% to $1.63 billion, translating to diluted earnings per share of $14.33, a significant increase from the prior year. This strong financial performance reflects the company's expanding commercial reach and the continued success of its late-stage pipeline. Looking ahead, Regeneron's pipeline remains robust, with several key products in advanced clinical development and ongoing regulatory reviews. The company's strategic collaborations, particularly with Sanofi and Bayer, continue to drive significant revenue. Management's focus remains on advancing its broad pipeline of innovative therapies while strategically deploying capital, including ongoing share repurchase programs, to enhance shareholder value. Investors should monitor the company's progress in key therapeutic areas and the impact of ongoing research and development efforts on future growth.

Regeneron Pharmaceuticals, Inc. reported a strong second quarter and first half of 2021, demonstrating significant growth across key financial metrics. Total revenues surged by 163% year-over-year to $5.14 billion for the quarter and by 105% to $7.67 billion for the first half, driven primarily by substantial net product sales, notably from REGEN-COV, and robust collaboration revenues. Net income followed suit, increasing by over 240% to $3.10 billion for the quarter and by 177% to $4.21 billion for the first half. Diluted earnings per share also saw a substantial increase, reflecting the company's improved profitability. Despite strong revenue growth, operating expenses also increased, particularly cost of goods sold and selling, general, and administrative expenses, largely due to the commercialization of REGEN-COV and increased headcount. The company's balance sheet remains strong, with total assets growing to $21.49 billion and substantial cash and marketable securities. Regeneron also continued its share repurchase program, buying back $612.1 million worth of common stock in the first half of the year. The company's robust performance underscores the significant impact of REGEN-COV and continued strength in key products like EYLEA and Dupixent.

Regeneron Pharmaceuticals, Inc. reported a strong first quarter of 2021, with total revenues reaching $2.53 billion, a significant increase from $1.83 billion in the same period last year. This growth was primarily driven by substantial increases in net product sales, particularly for EYLEA and Dupixent, as well as significant collaboration revenue from Sanofi and Bayer. Net income rose to $1.12 billion, or $10.09 per diluted share, up from $624.6 million, or $5.43 per diluted share, in the prior year's first quarter. The company also saw positive contributions from REGEN-COV, its COVID-19 antibody cocktail, which generated $438.8 million in net product sales. The balance sheet remains strong, with total assets increasing to $17.77 billion and stockholders' equity growing to $11.98 billion. The company also continues its share repurchase program, with $1.177 billion remaining available as of March 31, 2021. Key drivers of this performance include robust sales growth for flagship products like EYLEA and Dupixent, further strengthened by contributions from REGEN-COV. The company's strategic collaborations with Sanofi and Bayer continue to yield significant collaboration revenue, highlighting the strength of these partnerships. Despite ongoing investments in research and development, which increased year-over-year, Regeneron demonstrated strong operational efficiency, leading to substantial growth in operating income and net income. The company's financial position is solid, with ample liquidity to support ongoing operations, R&D initiatives, and capital expenditures, including significant investments in manufacturing facility expansions.

Regeneron Pharmaceuticals, Inc. reported strong financial performance for the nine months ended September 30, 2020, with total revenues increasing by 29% year-over-year to $6.1 billion and net income growing by 79% to $2.4 billion. This growth was driven by robust net product sales, particularly from EYLEA and Dupixent, and significant increases in collaboration revenue, notably from Sanofi. The company also made substantial investments in research and development, reflecting its commitment to pipeline expansion, including significant progress on REGN-COV2, its antibody cocktail for COVID-19. Financially, Regeneron maintained a strong liquidity position with over $1.5 billion in cash and cash equivalents and over $4.3 billion in marketable securities as of September 30, 2020. The company also successfully raised $2 billion in senior unsecured notes in August 2020 to support its operations. Despite ongoing patent litigation and regulatory scrutiny, particularly concerning Praluent and Eylea, Regeneron demonstrated resilience and continued growth, underscoring its strong market position and product pipeline.

Regeneron Pharmaceuticals, Inc. (REGN) reported a strong second quarter of 2020, with significant increases in both revenue and net income compared to the prior year. Total revenues grew by approximately 24% to $1.95 billion, driven by substantial growth in net product sales for Dupixent and Libtayo, along with increased collaboration revenue from Sanofi. Net income more than quadrupled year-over-year, reaching $897.3 million, or $7.61 per diluted share. This financial performance reflects the robust commercial execution across key products and ongoing advancements in the company's extensive clinical pipeline, including progress on REGN-COV2 for COVID-19. Despite the positive financial results, the company is navigating a complex operating environment due to the COVID-19 pandemic, which has impacted clinical trial enrollment and supply chain operations, though management has stated no material impact on financial statements as of this report. Significant events during the quarter included the end of the Praluent collaboration with Sanofi, with Regeneron now solely responsible for U.S. commercialization. Additionally, Sanofi completed a significant sale of its Regeneron shares, reducing its ownership stake. The company also continued its share repurchase program, demonstrating a commitment to returning capital to shareholders.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong financial results for the first quarter of 2020, driven by significant growth in net product sales and collaboration revenues. Total revenues increased by approximately 33% year-over-year to $1.83 billion. Net income saw a substantial rise of 35% to $624.6 million, with diluted earnings per share increasing from $3.99 to $5.43. This performance was largely fueled by robust sales of key products like EYLEA and Dupixent, with Dupixent showing a notable 129% increase in global net sales. The company also highlighted its strategic decision to take full responsibility for Praluent's commercialization in the U.S. starting April 1, 2020, along with receiving a royalty on Sanofi's ex-U.S. sales. The company's balance sheet remains strong, with total assets growing to $15.76 billion and cash and marketable securities increasing to $7.24 billion. Operating activities generated $698 million in cash. While research and development expenses increased by 20% to $583.9 million, reflecting ongoing investment in its pipeline, the company maintained robust profitability and liquidity. The report also touches upon the evolving landscape of collaborations, particularly with Sanofi, and acknowledges the potential impact of the COVID-19 pandemic on future operations and clinical trials, while stating no material impact was observed in the current quarter's financials.

Regeneron Pharmaceuticals, Inc. reported strong revenue growth for the nine months ended September 30, 2019, with total revenues reaching $5.7 billion, a 19% increase year-over-year. This growth was primarily driven by robust net product sales, notably EYLEA, which saw a 12% increase globally, and significant gains in Dupixent, Praluent, and Kevzara driven by collaboration revenue. Net income for the period was $1.32 billion, a decrease compared to the prior year, largely due to a substantial $400 million upfront payment made to Alnylam for a new collaboration and increased research and development expenses. Despite the decrease in net income, the company maintained a healthy cash position and a positive cash flow from operations.

Regeneron Pharmaceuticals, Inc. reported a notable increase in revenues for the six months ended June 30, 2019, reaching $3.65 billion, up from $3.12 billion in the prior year period. This growth was primarily driven by a strong performance in net product sales, particularly EYLEA in the U.S., and increased collaboration revenue from Sanofi and Bayer. Despite revenue growth, net income saw a significant decrease to $654.2 million from $1.03 billion in the same period last year. This decline is largely attributable to a substantial increase in research and development (R&D) expenses, which more than doubled to $1.69 billion, heavily impacted by a $400 million upfront payment made to Alnylam Pharmaceuticals for a new collaboration. The company's balance sheet shows an increase in total assets to $13.17 billion from $11.73 billion, bolstered by higher marketable securities and property, plant, and equipment, though cash and cash equivalents decreased. Key operational highlights include continued strong performance of EYLEA and significant advancements in the clinical pipeline for several key products like Dupixent and Libtayo, with regulatory submissions and approvals noted. The company also advanced its collaboration strategy with the Alnylam deal. However, investors should be mindful of the increased R&D spending, potential litigation risks (particularly concerning Praluent and EYLEA patents), and the company's continued reliance on key collaborations, especially with Sanofi and Bayer, for revenue generation and market access.

Regeneron Pharmaceuticals, Inc. reported strong revenue growth for the first quarter of 2019, with total revenues reaching $1.71 billion, a 13.2% increase compared to the prior year period. This growth was primarily driven by a significant increase in U.S. net product sales of EYLEA and strong performance in collaboration revenues from Sanofi and Bayer. Net income for the quarter was $461.1 million, or $3.99 per diluted share, showing a slight decrease from the previous year's $478.0 million, or $4.16 per diluted share, impacted by higher operating expenses, particularly in research and development and selling, general, and administrative functions. The company continues to invest heavily in its robust pipeline, with R&D expenses increasing by approximately 28.7% year-over-year. Despite increased operating costs, Regeneron demonstrated solid operational cash flow generation, with cash flow from operating activities increasing significantly to $897.0 million. The company also maintained a strong liquidity position with $5.57 billion in financial assets at the end of the quarter, including cash and marketable securities.

Regeneron Pharmaceuticals, Inc. reported strong financial performance for the nine months ended September 30, 2018, with total revenues reaching $4.78 billion, a significant increase from $4.29 billion in the prior year period. Net income also saw a substantial rise to $1.62 billion from $1.02 billion, translating to diluted earnings per share of $14.14, up from $8.84 in the same period last year. This growth was primarily driven by robust net product sales, particularly for EYLEA in the U.S., which increased by $270.7 million to $2.99 billion. Collaboration revenues also contributed positively, with significant growth from the Bayer EYLEA collaboration. The company's balance sheet strengthened, with total assets growing to $10.81 billion, supported by a healthy increase in cash and cash equivalents and marketable securities, indicating strong liquidity. The company also made notable progress on its product pipeline. Key developments include the FDA approval of Libtayo for advanced cutaneous squamous cell carcinoma and expanded indications for Dupixent in asthma. The company is actively investing in its manufacturing capabilities and continues to advance its numerous product candidates across various therapeutic areas, underscoring a strong commitment to future growth and innovation. Despite ongoing patent litigations, particularly concerning Praluent and Dupixent, the financial results demonstrate operational strength and successful commercial execution.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong financial performance for the second quarter and first half of 2018. Total revenues increased by 9.4% year-over-year in the second quarter to $1.61 billion and by 11.8% in the first half to $3.12 billion. This growth was primarily driven by a 7.9% increase in U.S. net product sales of EYLEA and significant collaboration revenue from Bayer, which rose by 25.1% in the second quarter. Net income saw substantial growth, increasing by 42.3% in the second quarter to $551.4 million ($4.82 per diluted share) and by 61.7% in the first half to $1.03 billion ($8.97 per diluted share). This impressive profitability was supported by effective cost management and a lower effective tax rate following the Tax Cuts and Jobs Act. The company also highlighted progress across its product pipeline, including positive developments for Dupixent in adolescent patients and cemiplimab for advanced cutaneous squamous cell carcinoma, reinforcing its position as a leading biopharmaceutical innovator.

Regeneron Pharmaceuticals, Inc. reported a strong first quarter for 2018, with net income soaring to $478.0 million, or $4.16 per diluted share, a significant increase from $248.9 million, or $2.16 per diluted share, in the prior year's first quarter. This growth was driven by a 14.6% increase in total revenues, reaching $1.51 billion, largely propelled by robust net product sales of EYLEA in the United States, which grew by 15.2% to $984.0 million. Collaboration revenues also saw a healthy increase, particularly from Bayer, which grew by 28.3% to $247.9 million, though Sanofi collaboration revenue saw a slight decrease. Key operational highlights include continued strong performance in clinical development pipelines, with significant progress noted for Dupixent, Cemiplimab, and EYLEA. The company also adopted new accounting standards (ASC 606) which impacted revenue recognition timing from collaboration agreements, resulting in a reclassification of revenue and a reduction in retained earnings. Despite ongoing legal proceedings related to patent infringements, particularly concerning Praluent and Dupixent, the company appears financially sound, with a substantial increase in cash and cash equivalents and a solid balance sheet. Investors can look forward to continued pipeline advancements and product commercialization efforts.

Regeneron Pharmaceuticals, Inc. reported strong financial performance for the nine months ended September 30, 2017. Total revenues increased by 17.5% year-over-year to $4.29 billion, driven by robust growth in net product sales of EYLEA and significant increases in collaboration revenues from Sanofi and Bayer. Net income saw a substantial increase of 59.5% to $1.02 billion, with diluted earnings per share rising to $8.84 from $5.51 in the prior year period. This growth reflects continued strong demand for key products and successful advancement of strategic collaborations, indicating positive momentum for the company. The company's balance sheet also reflects healthy growth, with total assets increasing to $8.70 billion from $6.97 billion at the end of 2016, primarily due to increases in cash, marketable securities, and property, plant, and equipment. Total stockholders' equity significantly increased to $6.05 billion from $4.45 billion, driven by retained earnings. These financial highlights demonstrate a solid operational and financial footing for Regeneron, supporting its ongoing research and development efforts and commercialization of its product portfolio.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong financial results for the second quarter and the first half of 2017, demonstrating significant revenue and net income growth compared to the prior year. Total revenues reached $1.47 billion for Q2 and $2.79 billion for H1 2017, driven by robust performance in net product sales and collaboration revenues from Sanofi and Bayer. Key drivers of this growth include strong demand for EYLEA in the U.S. and positive contributions from newly approved products like Dupixent and Kevzara. The company's strategic collaborations, particularly with Sanofi and Bayer, continue to be a significant factor in its financial success, with increasing collaboration revenues and reimbursements for research and development expenses. Despite ongoing legal proceedings, particularly related to Praluent, Regeneron's financial health appears robust, supported by a strong balance sheet and positive operating cash flows.

Regeneron Pharmaceuticals, Inc. reported solid financial results for the first quarter of 2017, demonstrating robust revenue growth and improved profitability compared to the same period in the prior year. Total revenues increased by approximately 10% year-over-year, driven by strong net product sales, primarily from EYLEA, and growth in collaboration revenues. Net income saw a significant increase, reflecting improved operational efficiency and strong top-line performance. The company's balance sheet remains healthy, with a substantial increase in cash and cash equivalents and a solid working capital position, providing financial flexibility for ongoing research and development activities and strategic investments. The company's pipeline continues to advance, with key product candidates progressing through clinical trials. Significant regulatory milestones were achieved with the U.S. FDA approval of Dupixent for atopic dermatitis and Health Canada approval for Kevzara for rheumatoid arthritis. These advancements, coupled with the continued success of EYLEA and growing contributions from other collaborations, position Regeneron favorably for future growth. Investors should monitor ongoing patent litigation related to Praluent and regulatory developments for key pipeline assets.

Regeneron Pharmaceuticals, Inc. reported solid financial results for the third quarter and first nine months of 2016, demonstrating strong revenue growth driven primarily by EYLEA sales. Total revenues increased by 7% for the quarter and 21% year-to-date, reaching $1.22 billion and $3.63 billion, respectively. Net income also saw a significant rise, up 26% for the quarter and 33% year-to-date, reaching $264.8 million and $642.4 million, respectively. This growth reflects successful commercialization efforts for EYLEA and continued progress in key collaboration programs with Sanofi and Bayer. Key developments include ongoing clinical trials for several promising product candidates, notably Dupixent for allergic and inflammatory conditions, and Praluent for cholesterol management. The company's investment in research and development remains robust, indicating a commitment to expanding its pipeline. Despite legal challenges, particularly concerning Praluent, and the ongoing costs associated with its extensive pipeline, Regeneron's financial performance appears strong and positioned for continued growth, supported by its strategic collaborations and its core product, EYLEA.

Regeneron Pharmaceuticals, Inc. reported strong financial performance for the second quarter and first half of 2016, driven by significant growth in EYLEA net product sales. Total revenues increased year-over-year for both periods, with the first half of 2016 reaching $2.41 billion, up from $1.87 billion in the prior year. Net income also saw a substantial rise, reaching $377.6 million for the first half of 2016, compared to $270.7 million in the same period of 2015. The company's operating expenses increased due to expanded R&D and commercialization activities, including a notable rise in R&D expenses driven by new collaborations and expanded clinical trials. Despite increased spending, the company demonstrated robust top-line growth and improved profitability.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong top-line growth in its first quarter 2016 filing, with total revenues increasing to $1.20 billion from $869.6 million in the prior year period. This substantial growth was primarily driven by a significant increase in net product sales, particularly from EYLEA, which saw U.S. sales rise to $780.9 million from $541.1 million in Q1 2015. Collaboration revenues from Sanofi and Bayer also showed healthy growth, indicating the continued strength of key partnerships. The company's net income more than doubled to $165.7 million, or $1.45 per diluted share, compared to $76.0 million, or $0.66 per diluted share, in the first quarter of 2015. This improved profitability reflects not only the robust revenue growth but also increased operating expenses, largely due to expanded research and development and commercialization activities. Despite increased R&D spending, the company's financial performance demonstrates a positive trajectory driven by its core products and expanding pipeline.

Regeneron Pharmaceuticals, Inc. (REGN) reported a significant increase in revenue and net income for the nine months ended September 30, 2015, compared to the same period in the prior year. This growth was driven primarily by strong performance in net product sales, notably Eylea, and robust collaboration revenues from Sanofi and Bayer HealthCare. The company also announced the FDA approval of Praluent in July 2015, marking a key milestone in its cholesterol-lowering franchise, and has a strong pipeline of antibody-based candidates in various stages of clinical development across multiple therapeutic areas. Financially, Regeneron demonstrated substantial revenue growth, with total revenues reaching $3,005.7 million for the nine months ended September 30, 2015, a significant increase from $2,017.2 million in the prior year. Net income more than doubled, reaching $481.1 million, or $4.18 per diluted share, compared to $248.0 million, or $2.19 per diluted share, in the corresponding period of 2014. The company's balance sheet strengthened, with total assets growing to $5,182.9 million and stockholders' equity increasing significantly, reflecting its growing profitability and continued investment in its business. The company also continues to generate substantial operating cash flow, providing flexibility for ongoing research, development, and strategic initiatives.

Regeneron Pharmaceuticals, Inc. reported strong financial results for the quarter ended June 30, 2015, driven by significant growth in EYLEA net product sales, which increased by 58% year-over-year to $654.6 million. Total revenues grew 50% to $998.6 million, and net income more than doubled to $194.6 million. The company's strategic collaborations with Sanofi and Bayer HealthCare continue to be a major revenue driver, with Sanofi collaboration revenue up 37% and Bayer HealthCare collaboration revenue up 38% in the quarter. The company also made significant progress in its pipeline, with the FDA approving Praluent (alirocumab) for the treatment of high LDL cholesterol in July 2015. This approval, coupled with robust clinical trial data for other pipeline candidates like dupilumab and sarilumab, indicates a promising future for Regeneron. The company's ongoing investment in research and development remains high, reflecting its commitment to innovation and future growth, supported by a substantial cash position and an undrawn credit facility.

Regeneron Pharmaceuticals, Inc. reported strong revenue growth in the first quarter of 2015, driven primarily by a significant increase in EYLEA net product sales, which rose to $541.1 million from $359.0 million in the prior year's comparable quarter. This 50% year-over-year increase highlights the continued market adoption and success of EYLEA for its approved ophthalmic indications. Collaboration revenue also saw a healthy increase, particularly from the Sanofi partnership, bolstered by the amended ZALTRAP agreement and increased reimbursements for antibody development, signaling robust progress in their joint development programs for key pipeline assets like Praluent and Dupilumab. The company's net income grew to $76.0 million, or $0.66 per diluted share, compared to $68.3 million, or $0.61 per diluted share, in the first quarter of 2014. While research and development expenses increased, reflecting continued investment in their extensive pipeline, the company also benefited from strong collaboration revenue and managed its selling, general, and administrative expenses effectively. Regeneron ended the quarter with a solid cash position, although cash used in operating activities was negative, largely due to an increase in accounts receivable. The company also secured a new $750 million revolving credit facility, enhancing its financial flexibility.

Regeneron Pharmaceuticals, Inc. reported solid financial results for the nine months ended September 30, 2014, with total revenues reaching $2.02 billion, a significant increase from $1.49 billion in the same period of 2013. This growth was primarily driven by strong net product sales, largely from EYLEA, which saw a substantial increase in sales volume. Collaboration revenue from Sanofi and Bayer HealthCare also contributed positively, reflecting progress in key development programs and expanded EYLEA indications. The company's net income for the period was $237.9 million, down from $327.6 million in the prior year, largely due to a significant increase in research and development (R&D) expenses, which climbed to $919.6 million from $591.8 million, reflecting substantial investments in late-stage clinical programs like alirocumab and dupilumab, and a one-time charge related to a priority review voucher purchase. Financially, Regeneron strengthened its balance sheet with cash, cash equivalents, and marketable securities increasing to $1.49 billion. The company also successfully managed its debt, converting a portion of its convertible senior notes. Despite increased R&D spending and a one-time charge impacting profitability year-over-year, the overall financial health appears robust, supported by strong product sales and strategic collaborations. The company remains focused on advancing its broad pipeline, with significant progress noted across its antibody-based clinical programs and trap-based programs, positioning it for potential future growth.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong revenue growth for the second quarter and first half of 2014, driven primarily by robust sales of EYLEA. Total revenues reached $665.7 million for the quarter and $1.29 billion for the first half, representing significant increases year-over-year. Net income was $92.7 million in Q2 2014, up from $87.4 million in Q2 2013, though net income for the first half of 2014 decreased to $158.2 million from $186.3 million in the prior year, impacted by higher research and development expenses and a significant increase in income tax expense. The company also saw increased collaboration revenue from both Sanofi and Bayer HealthCare, highlighting the progress in its key partnerships. The company's pipeline continues to advance, with notable progress in late-stage antibody programs like alirocumab and dupilumab. EYLEA received FDA approval for diabetic macular edema (DME) in July 2014, further expanding its market potential. Significant investments in research and development were made, particularly in clinical trials for key antibody candidates. Financially, Regeneron maintained a strong cash position, ending the period with over $1.36 billion in cash and marketable securities.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong top-line growth in the first quarter of 2014, with total revenues increasing by 42% year-over-year to $625.7 million. This growth was primarily driven by a 14% increase in Net Product Sales, largely due to higher volumes of EYLEA in the U.S., and a significant surge in Collaboration Revenue. Collaboration Revenue more than doubled to $255.8 million, propelled by substantial increases in revenue from Sanofi and Bayer HealthCare, reflecting strong performance in EYLEA sales outside the U.S. and key milestone payments. Despite this revenue expansion, net income decreased by 34% to $65.4 million, or $0.58 per diluted share, compared to $98.9 million, or $0.90 per diluted share in the prior year. This decrease was primarily due to a significant increase in Research and Development expenses, which rose 59% year-over-year to $287.4 million, and a substantially higher effective tax rate of 62.7% in the current quarter compared to 30.3% in the prior year quarter. The company continues to invest heavily in its pipeline, with ongoing clinical trials for key drug candidates like alirocumab and dupilumab showing progress. Significant milestones were achieved in the quarter, including the submission of a supplemental BLA for EYLEA in DME and positive Phase 3 results for EYLEA in BRVO. The company also received significant collaboration revenue from Bayer HealthCare related to EYLEA milestones and the PDGFR-beta antibody agreement. While the company's overall financial position remains strong with substantial cash and marketable securities, the increased R&D spending and higher tax rate present headwinds to near-term profitability, though the robust revenue growth and pipeline progress are positive indicators for long-term investor value.

Regeneron Pharmaceuticals, Inc. (REGN) reported a strong third quarter and first nine months of 2013, driven by significant growth in EYLEA® net product sales in the U.S. Total revenues increased by 40% in Q3 2013 to $597.0 million and by 55% for the nine-month period to $1,494.3 million compared to the prior year. This growth was bolstered by milestone payments from collaborations with Bayer HealthCare related to EYLEA's international commercialization. Despite increased operating expenses, primarily in research and development and selling, general, and administrative functions due to headcount expansion and increased clinical trial activities, the company maintained profitability. Net income for Q3 2013 was $141.3 million, or $1.25 per diluted share, and $327.6 million, or $2.95 per diluted share, for the nine months. The company's cash position also strengthened, with cash, cash equivalents, and marketable securities reaching $775.2 million at the end of the period.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong financial performance for the second quarter and first half of 2013, primarily driven by the continued success of its lead product, EYLEA. Total revenues significantly increased year-over-year, reaching $457.6 million in Q2 2013 and $897.3 million in the first half, up from $304.4 million and $536.2 million in the respective periods of 2012. This growth was largely fueled by EYLEA net product sales, which nearly doubled in the second quarter to $329.8 million. The company also saw an increase in net income to $87.4 million ($0.79 per diluted share) for Q2 2013 and $186.3 million ($1.69 per diluted share) for the first half of 2013, a notable improvement from the prior year. Beyond EYLEA, Regeneron continues to advance its robust pipeline of antibody-based and Trap-based product candidates through significant collaborations with Sanofi and Bayer HealthCare. The company's strategic investments in research and development are reflected in increased R&D expenses, which are partially offset by collaboration revenue. The company also made progress on its infrastructure, including new lease agreements for expanded facilities, signaling a commitment to future growth. Overall, Regeneron demonstrates a strong growth trajectory driven by its key products and a promising pipeline.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong first-quarter 2013 financial results, demonstrating significant growth and improved profitability. Total revenues surged to $439.7 million, a substantial increase from $231.8 million in the prior year's quarter, primarily driven by the robust performance of EYLEA. Net income rose dramatically to $98.9 million, or $0.90 per diluted share, from $11.7 million, or $0.11 per diluted share, in Q1 2012, showcasing the company's expanding profitability. The company's flagship product, EYLEA, continues to be the primary growth engine, with U.S. net product sales reaching $313.9 million, more than doubling from $123.5 million in the same period last year. Collaboration revenues also saw a healthy increase, contributing $114.2 million, bolstered by contributions from Sanofi and Bayer HealthCare. These positive financial trends reflect the successful commercialization of key products and the ongoing advancement of Regeneron's diverse pipeline.

Regeneron Pharmaceuticals, Inc. (REGN) reported a significant turnaround in its financial performance for the nine months ended September 30, 2012, transitioning from a net loss in the prior year to a substantial net income. This shift is primarily driven by the successful launch and strong sales of EYLEA® (aflibercept) Injection for ophthalmological conditions, which began in November 2011. The company also benefited from milestone payments related to ZALTRAP® (ziv-aflibercept) Injection and EYLEA approvals in new markets. Operating expenses saw an increase, largely due to expanded headcount and commercialization efforts for EYLEA, alongside ongoing investments in research and development for its robust pipeline of antibody-based and trap-based drug candidates. The company maintains a strong cash and marketable securities position, indicating financial stability to support its ongoing development and commercialization activities.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong financial performance for the six months ended June 30, 2012, driven by the successful launch and sales of its flagship product, EYLEA®. Total revenues significantly increased to $536.2 million from $220.0 million in the prior year period, primarily due to $317.5 million in EYLEA net product sales. This robust top-line growth translated into a net income of $88.4 million for the first half of 2012, a substantial improvement from a net loss of $106.0 million in the comparable period of 2011. The company's strategic collaborations with Sanofi and Bayer HealthCare continue to be significant revenue drivers, contributing $174.0 million and $21.6 million, respectively, in collaboration revenue. Research and development expenses increased to $286.2 million, reflecting ongoing investment in its extensive pipeline of antibody-based and Trap-based product candidates across various therapeutic areas. The company ended the period with a healthy liquidity position, holding $425.4 million in marketable securities and $172.0 million in cash and cash equivalents.

Regeneron Pharmaceuticals, Inc. (REGN) reported a significant shift from a net loss in Q1 2011 to a net income of $11.7 million ($0.11/diluted share) in Q1 2012. This turnaround was primarily driven by the launch of EYLEA® (aflibercept) Injection for wet age-related macular degeneration (AMD) in November 2011, which generated $123.5 million in net product sales during the quarter. Total revenues surged to $231.8 million, up from $112.2 million in the prior year's quarter, largely due to EYLEA's performance and sustained collaboration revenues from Sanofi and Bayer HealthCare. While R&D expenses increased to $138.9 million, reflecting ongoing clinical development, Selling, General, and Administrative expenses also rose significantly to $58.4 million, driven by EYLEA's commercialization efforts. Despite increased operating expenses, the strong product sales of EYLEA have propelled the company to profitability. Regeneron continues to advance a robust pipeline with 13 product candidates in clinical development, including EYLEA for other eye diseases, ZALTRAP® for oncology in collaboration with Sanofi, and ARCALYST® for gout flares.

Regeneron Pharmaceuticals, Inc. (REGN) reported a net loss of $62.4 million for the third quarter of 2011, an increase from the $33.9 million net loss in the same period of 2010. This wider loss was primarily driven by higher selling, general, and administrative expenses, and increased research and development spending. Total revenues remained relatively flat year-over-year, at $102.8 million for Q3 2011 compared to $106.0 million for Q3 2010, with collaboration revenues from Sanofi and Bayer HealthCare forming the largest portion. The company's cash and marketable securities position stood at $511.7 million at the end of the third quarter of 2011, bolstered by a recent $400 million convertible senior notes offering. Key developments during the period include progress in the clinical development and regulatory pathways for EYLEATM (aflibercept injection) for wet Age-Related Macular Degeneration (AMD), with a BLA submission and Priority Review status from the FDA, though the review target date was extended. ZALTRAP® (aflibercept) also showed positive Phase 3 results for metastatic colorectal cancer, with planned regulatory submissions. The company continues to invest heavily in its extensive pipeline of antibody-based candidates, particularly in collaboration with Sanofi. The substantial increase in operating expenses, especially in SG&A and R&D, reflects significant investments in commercialization preparations for EYLEATM and ongoing pipeline advancement.

Regeneron Pharmaceuticals, Inc. (REGN) reported a net loss of $62.5 million ($0.69 per share) for the second quarter ended June 30, 2011, an increase from the $25.5 million ($0.31 per share) net loss in the same period of 2010. This wider loss was driven primarily by increased research and development (R&D) expenses and higher selling, general, and administrative (SG&A) costs, reflecting the company's ongoing investments in its extensive pipeline. Total revenues for the quarter were $107.8 million, a slight decrease from $115.9 million in Q2 2010, impacted by lower technology licensing revenue. Collaboration revenues from Sanofi and Bayer HealthCare remained robust, primarily driven by expense reimbursements for ongoing development programs. Notably, the company submitted a Biologics License Application (BLA) for EYLEATM for wet age-related macular degeneration (AMD) in February 2011, which received Priority Review with a target decision date in August 2011. Positive results were also reported for ZALTRAPTM in colorectal cancer and ARCALYST® for gout flares, with regulatory submissions planned. The company ended the quarter with $254.3 million in cash and cash equivalents and $55.4 million in marketable securities, reflecting significant cash burn but also substantial collaboration funding.

Regeneron Pharmaceuticals, Inc. reported a net loss of $43.4 million for the first quarter of 2011, an increase from the $30.5 million loss in the same period of 2010. This widening loss was driven by higher research and development (R&D) expenses and increased selling, general, and administrative (SG&A) costs. Total revenues grew to $112.2 million, up from $103.5 million in Q1 2010, primarily due to increased collaboration revenue from its partnerships with sanofi-aventis and Bayer HealthCare. The company continues to advance its late-stage pipeline, with significant progress noted in the regulatory submission for VEGF Trap-Eye and positive results from trials for ZALTRAP™ and ARCALYST®. Financially, Regeneron's cash, cash equivalents, and marketable securities stood at $607.6 million at the end of the quarter. The company utilized $10.6 million in cash from operations, but also saw positive cash flow from investing activities due to the net sale of marketable securities. Management expressed confidence in their ability to fund operations through at least 2013, supported by existing capital and expected reimbursements from collaborators, though substantial future funding requirements for R&D and potential commercialization remain.

Regeneron Pharmaceuticals, Inc. reported a net loss of $33.9 million for the third quarter of 2010, an increase from the $1.0 million net loss in the same period of 2009. This widened loss was primarily driven by a significant increase in research and development expenses. Total revenues for the quarter decreased to $106.0 million from $117.5 million year-over-year, impacted by lower collaboration revenue from Bayer HealthCare, partly offset by increased collaboration revenue from sanofi-aventis, driven by antibody research activities. The company continues to invest heavily in its robust pipeline, with a strong focus on its antibody collaboration with sanofi-aventis and its VEGF Trap-Eye program with Bayer HealthCare. Notably, Regeneron received a significant $165 million upfront payment in August 2010 from Astellas Pharma Inc. related to an extended technology licensing agreement. Despite the net loss, the company's liquidity remains strong, with cash, cash equivalents, and marketable securities totaling $520.4 million as of September 30, 2010, bolstered by a public offering of common stock in October 2010 that raised approximately $174.7 million.

Regeneron Pharmaceuticals, Inc. reported a net loss of $25.5 million ($0.31 per share) for the second quarter ended June 30, 2010, an increase from the $14.9 million loss ($0.19 per share) in the same period of 2009. This widened loss was primarily driven by higher research and development (R&D) expenses, which rose to $124.5 million from $94.2 million year-over-year, largely due to expanded R&D activities related to the company's antibody collaboration with sanofi-aventis. Despite the increased loss, total revenues grew to $115.9 million from $90.0 million, bolstered by strong performance in collaboration revenues, particularly from sanofi-aventis. Net product sales for ARCALYST® increased to $5.2 million from $4.5 million. The company also announced positive results from its PRE-SURGE 1 Phase 3 study for ARCALYST® in gout flare prevention, a significant development for a key pipeline asset. Management believes current capital resources, including expected funding from collaborations, are sufficient to meet operating needs through at least 2013.

Regeneron Pharmaceuticals, Inc. (REGN) reported its first quarter 2010 financial results, showing a significant increase in revenue driven by collaboration and product sales, though the company also experienced an increased net loss. Total revenues grew to $103.5 million from $75.0 million in the prior year period, primarily due to higher collaboration revenues from sanofi-aventis and Bayer HealthCare, alongside a substantial increase in net product sales from ARCALYST®. Despite revenue growth, the net loss widened to $30.5 million ($0.38 per share) from $15.4 million ($0.19 per share) in Q1 2009. This was largely driven by a significant increase in research and development (R&D) expenses, particularly related to clinical trials for key pipeline candidates like VEGF Trap-Eye and various antibody programs. The company continues to advance its late-stage clinical programs in oncology and ophthalmology, with several key data readouts expected in late 2010 and early 2011.

Regeneron Pharmaceuticals, Inc. (REGN) reported its financial results for the third quarter and the first nine months ended September 30, 2009. The company's net loss narrowed significantly compared to the prior year, primarily driven by increased contract research and development revenue, particularly from collaborations with sanofi-aventis and Bayer HealthCare. A notable contributor to revenue was a $20 million research progress payment received from Bayer HealthCare. ARCALYST® (rilonacept) net product sales also showed an increase. Research and development expenses increased year-over-year, reflecting expanded R&D activities, notably in the antibody collaboration with sanofi-aventis. The company continues to invest heavily in its pipeline, with ongoing Phase 3 trials for aflibercept in oncology and VEGF Trap-Eye in ophthalmology. Significant updates on clinical trial progress were provided, including enrollment statuses and expected data releases. The company's liquidity remains strong, with substantial cash, cash equivalents, and marketable securities, and management anticipates sufficient capital to fund operations through at least 2012.

Regeneron Pharmaceuticals, Inc. (REGN) reported its financial results for the second quarter and first half of 2009. The company continues to operate at a net loss, with a loss of $14.9 million for Q2 2009 and $30.3 million for the first half of 2009. Despite the losses, revenues showed a significant increase, driven by higher contract research and development revenue from collaborations with sanofi-aventis and Bayer HealthCare, as well as increased net product sales of ARCALYST®. Research and development expenses also increased, reflecting the company's expanding pipeline and ongoing clinical trials. Key financial developments include a strengthening cash position and strategic shifts in the company's investment portfolio towards higher-quality securities. Regeneron also reported progress in its late-stage clinical programs for aflibercept and VEGF Trap-Eye, with enrollment continuing and initial data expected in 2010. The company noted a significant amendment to its Tarrytown, NY lease agreement and provided an update on its collaboration with Bayer HealthCare for VEGF Trap-Eye, including a recently received $20 million milestone payment.